Salute e Benessere

T-Therapeutics announces Series A extension to $91 million to advance…

$32 million new equity injection adds to previously announced $59 millionNew investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England– T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing,...
Nasdaq GlobeNewswire
13/11/2025

Robert Lewandowski Named Global Brand Ambassador for KSM-66 Ashwagandha

The partnership pairs Lewandowski's two-decade career at football's elite level with KSM-66 Ashwagandha's commitment to 4000 year old Ayurvedic tradition of root-only extraction. His consistency across leagues and clubs, from Borussia Dortmund to Bayern Munich to FC Barcelona, mirrors the quality standards that define KSM-66's manufacturing approach. Manufactured by Ixoreal Biomed, KSM-66 Ashwagandha is trusted as a star ingredient in products of over 4,500 brands worldwide. The partnership...
PR Newswire
13/11/2025

Zealand Pharma Announces Financial Results for the First Nine Months of 2025

Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026.Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving...
Nasdaq GlobeNewswire
13/11/2025

WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical…

Key Takeaways from the WRN Inhibitors Market Report Key Takeaways from the WRN Inhibitors Market Report Discover which indication is expected to grab the major WRN inhibitors market share @WRN Inhibitors Market Report Key Factors Driving the WRN Inhibitors Market Synthetic Lethality Targeting in MSI Cancers WRN inhibitors exploit synthetic lethality by targeting the Werner syndrome helicase (WRN), critical for DNA repair in MSI-H tumors. Tumors with high microsatellite...
PR Newswire
12/11/2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum)…

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating to 99.2% under conventional per protocol analysis If approved, GanLum would represent first major innovation in malaria treatment since 1999, with potential to kill drug-resistant parasites and block transmissionNovel ingredient in...
Nasdaq GlobeNewswire
12/11/2025

Alvotech Reports Results for the First Nine Months of 2025 and Provides a…

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D...
Nasdaq GlobeNewswire
12/11/2025

Essity acquires Edgewell's feminine care business in North America including the…

"I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With this acquisition we are building a stronger personal care business in North America, in line with our strategy to focus on high yielding categories in attractive geographies." says Ulrika Kolsrud, President and CEO of Essity. "I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With…
PR Newswire
12/11/2025

Inventiva announces launch of public offering

Daix (France), New York City (New York, United States), November 12, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary…
Nasdaq GlobeNewswire
12/11/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from November 03rd to November 07th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1103/11/2025FR0010259150300...
Nasdaq GlobeNewswire
12/11/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of October 31, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (November 12, 2025 - 6:00 pm)– As of October 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
12/11/2025

IBA – TRANSPARENCY NOTIFICATION

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, November 12 th, 2025 06:00 PM Summary of the notificationIBA SA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the...
Nasdaq GlobeNewswire
12/11/2025

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™…

®Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has approved the Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC).The clinical study is an early feasibility clinical investigation and will...
Nasdaq GlobeNewswire
12/11/2025

Wandercraft and SAPA Announce Deployment Partnership in Industrial…

PARIS and ARPAIA, Italy, Nov.12, 2025(GLOBE NEWSWIRE) -- Wandercraft, a global leader in autonomous robotics, and SAPA, Italy-based ‘One-Shot Company’ and Tier 1 supplier renowned for its innovative approach to automotive parts manufacturing, today announced a Deployment Partnership to implement and scale deployment of Calvin-40, Wandercraft’s autonomous heavy-payload, modular humanoid robot, in SAPA’s industrial operations.This milestone builds on Wandercraft’s Strategic Partnership...
Nasdaq GlobeNewswire
12/11/2025

Head and Neck Cancer Drugs/Therapeutics Market Backed by Growing Adoption of…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=219003 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=219003 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Head and Neck Cancer Drugs/Therapeutics Market Overview 1. Rising Global Incidence and Growing Patient Population The Head and Neck Cancer Drugs/Therapeutics Market is significantly influenced by the increasing global incidence...
PR Newswire
12/11/2025

Hyaluronic Acid Based Dermal Fillers Market Poised for Remarkable Growth Driven…

For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market. For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market . Browse in-depth TOC 202 - Pages126 – Tables 37 – Figures Global Hyaluronic Acid Based Dermal Fillers Market Overview Market Driver 1. Rising Demand for Non-Surgical Aesthetic ProceduresThe increasing...
PR Newswire
12/11/2025

Dental Chairs Market to Reach $820.84 Million by 2027 in the short run and…

Request Sample of the Report on Dental Chairs Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/2658 Request Sample of the Report on Dental Chairs Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/2658 Market Introduction A dental chair is a specialized medical device designed to position patients ergonomically during dental procedures while ensuring optimal access for practitioners. These chairs feature adjustable headrests,...
PR Newswire
12/11/2025

Life Science Instrumentation Market worth $92.5 billion by 2031 with 6.5% CAGR |…

Browse in-depth TOC on "Life Science Instrumentation Market" Browse in-depth TOC on "Life Science Instrumentation Market" 300 - Tables 50 - Figures 400 - Pages By technology,the life science instrumentation market is segmented into spectroscopy, chromatography, polymerase chain reaction (quantitative PCR, digital PCR), immunoassays, lyophilization, liquid handling systems, clinical chemistry analyzers, microscopy, flow cytometry, next-generation sequencing, centrifuges,...
PR Newswire
12/11/2025

Fragrance Diffuser Market to Reach $55.1 billion, Globally, by 2034 at 6.7%…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Prime determinants of growth The demand for fragrance diffuser has increased as more consumers prioritize holistic well-being and seek natural ways to improve their mental and physical health. Aromatherapy, which uses essential oils to promote relaxation, reduce stress, and...
PR Newswire
12/11/2025

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for…

"We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission of transforming patients' lives with high quality radiopharmaceuticals drives every step of our work, and we are proud to contribute to bringing promising therapies in oncology closer to patients." said Bruno Paquin, CEO of AtomVie. "We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical…
PR Newswire
12/11/2025

/C O R R E C T I O N -- EirGenix, Inc./

EG1206A has completed its pharmacokinetic (PK) clinical study, and last month received positive feedback from both the U.S. FDA and the European Medicines Agency (EMA), confirming that the product qualifies for an abbreviated development pathway, allowing for the waiver of Phase III comparative efficacy trials. This agreement marks another major milestone and breakthrough in EirGenix's biosimilar development efforts. This partnership further strengthens the existing collaboration between Sandoz…
PR Newswire
12/11/2025

Chiesi Group Enters into an Exclusive License Agreement with Aliada…

“This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive and neurological symptoms across several rare diseases,”Giacomo Chiesi, Executive Vice President,Chiesi Global Rare Diseases. “These aspects of the disease are frequently underserved, yet they can profoundly affect patients and their families. By advancing this research, we intend to go beyond symptom management and potentially address the...
Nasdaq GlobeNewswire
12/11/2025

Keralty and Total Care Saudi (TCS) Form Strategic Alliance to Advance Population…

The alliance seeks to shift the focus of healthcare from reactive disease management to predictive and proactive health management, guiding the evolution of TCS's successful Third-Party Administrator (TPA) model into a next-generation Population Health Services Organization (PHSO). This transformation will center on the comprehensive, integrated care of populations before they require high-cost interventions, enabling smarter use of resources and better health outcomes. The alliance seeks to...
PR Newswire
12/11/2025

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025…

"This past month has been transformative for the Company, marked by closing a $58.88 million private placement led by Winklevoss Capital and successfully deploying $50 million to build a digital asset treasury designed to create long-term shareholder value focused on active participation in the development of Zcash and acquiring ZEC," said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. "In our drug development business, we presented the final data from our…
PR Newswire
12/11/2025

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and…

- Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 -- Next generation oncolytic virus VCN-12 preclinical data presented at the 32 ndAnnual Congress European Society of Gene & Cell Therapy (ESGCT) -- Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15...
Nasdaq GlobeNewswire
12/11/2025
Altri  Comunicati